Emodin suppresses oxaliplatin‐induced neuropathic pain by inhibiting COX2/NF‐κB mediated spinal inflammation
Authors:
- 2 October 2022
- journal article
- research article
- Published by Wiley in Journal of Biochemical and Molecular Toxicology
- Vol. 37 (1) , e23229
Abstract
Oxaliplatin (OXA) is a common chemotherapy drug for colorectal, gastric, and pancreatic cancers. The anticancer effect of OXA is often accompanied by neurotoxicity and acute and chronic neuropathy. The symptoms present as paresthesia and pain which adversely affect patients' quality of life. Herein, five consecutive intraperitoneal injections of OXA at a dose of 4 mg/kg were used to mimic chemotherapy. OXA administration induced mechanical allodynia, activated spinal astrocytes, and increased inflammatory response. To develop an effective therapeutic measure for OXA‐induced neuropathic pain, emodin was intrathecally injected into OXA rats. Emodin developed an analgesic effect, as demonstrated by a significant increase in the paw withdrawal threshold of OXA rats. Moreover, emodin treatment reduced the pro‐inflammatory cytokines (tumor necrosis factor‐α and interleukin‐1β) which upregulated in OXA rats. Furthermore, autodock data showed four hydrogen bonds were formed between emodin and cyclooxygenase‐2 (COX2), and emodin treatment decreased COX2 expression in OXA rats. Cell research further proved that emodin suppressed nuclear factor κB (NF‐κB)‐mediated inflammatory signal and reactive oxygen species level. Taken together, emodin reduced spinal COX2/NF‐κB mediated inflammatory signal and oxidative stress in the spinal cord of OXA rats which consequently relieved OXA‐induced neuropathic pain.Keywords
Funding Information
- National Natural Science Foundation of China (81971066, 81901149 and 32100823)
This publication has 60 references indexed in Scilit:
- Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapyEuropean Journal of Pharmaceutics and Biopharmaceutics, 2015
- Anti-Inflammatory Effect of Emodin via Attenuation of NLRP3 Inflammasome ActivationInternational Journal of Molecular Sciences, 2015
- Spinal neuroimmune activation is independent of T-cell infiltration and attenuated by A3 adenosine receptor agonists in a model of oxaliplatin-induced peripheral neuropathyBrain, Behavior, and Immunity, 2015
- Mechanism-based treatment for chemotherapy-induced peripheral neuropathic painNature Reviews Neurology, 2014
- Emodin has a protective effect in cases of severe acute pancreatitis via inhibition of nuclear factor-κB activation resulting in antioxidationMolecular Medicine Reports, 2014
- Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice GuidelineJournal of Clinical Oncology, 2014
- Emodin attenuates systemic and liver inflammation in hyperlipidemic mice administrated with lipopolysaccharidesExperimental Biology and Medicine, 2014
- A systematic review on chronic oxaliplatin-induced peripheral neuropathy and the relation with oxaliplatin administrationSupportive Care in Cancer, 2014
- Glia and pain: Is chronic pain a gliopathy?Pain, 2013
- Hepatoprotection of emodin andPolygonum multiflorumagainst CCl4-induced liver injuryPharmaceutical Biology, 2011